Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

FDA EMDAC schedules to review VIVUS' Qnexa NDA for treatment of obesity

VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review the Company's New Drug Application (NDA) for Qnexa for the treatment of obesity on February 22, 2012.

26 Dec 2011

AtheroNova establishes clear development plan for AHRO-001 after positive FDA feedback

AtheroNova Inc., a biotech company focused on the research and development of compounds to regress atherosclerotic plaque has established a clear development plan, including Phase I and Phase II protocol outlines, based on the recently finalized minutes of its pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its AHRO-001, a compound for the treatment of atherosclerosis.

15 Dec 2011

VIVUS announces results of Qnexa clinical study on cardiometabolic disease

VIVUS, Inc. today announced that results from the SEQUEL study were published in The American Journal of Clinical Nutrition, a peer-reviewed journal with broad, multidisciplinary readership.

9 Dec 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011

Clear link between erectile dysfunction and peripheral neuropathy

Spanish researchers have uncovered clear links between erectile dysfunction (ED) and peripheral neuropathy, according to a paper in the December issue of the urology journal BJUI.

15 Nov 2011

Multiple medication use may increase severity of erectile dysfunction

The use of multiple medications is associated with increased severity of erectile dysfunction, according to a Kaiser Permanente study published online in the British Journal of Urology International.

15 Nov 2011

Fears about ICD shock during sex leads to performance problems in heart patients

Adults with congenital heart disease and implanted cardioverter defibrillators (ICDs) often have a high level of fear and anxiety about the device delivering a shock during sex - resulting in sexual performance problems, according to research (Abstract 14165) presented at the American Heart Association's Scientific Sessions 2011.

14 Nov 2011

Medtronic highlights scientific sessions of interest on program for TCT 2011

Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.

From Medtronic 5 Nov 2011

FDA accepts VIVUS' Qnexa NDA for filing and review

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for Qnexa to treat obesity. The company resubmitted the NDA on October 17, 2011.

4 Nov 2011

Watson receives FDA approval for Androderm lower-dose formulations

Watson Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved its Androderm (testosterone transdermal system) 2 mg and 4 mg formulation.

21 Oct 2011

VIVUS announces Qnexa NDA resubmission for treatment of obesity

VIVUS, Inc. today announced that the company has resubmitted the New Drug Application (NDA) for Qnexa to the U.S. Food and Drug Administration.

18 Oct 2011

Restless legs syndrome linked to hypertension

Up to 15 percent of the population has restless legs syndrome. Restless legs syndrome is characterized by crawling sensations and repeated muscle twichings in one or both legs, and an uncontrollable urge to move them - which may compel a person to walk in circles for hours at night.

12 Oct 2011

NovaSom enters unique agreement with HealthAmerica to treat sleep disorders

NovaSom, Inc., the market leader in technology-driven, payer-aligned cost-saving solutions for obstructive sleep apnea (OSA) management, today announced it has entered a preferred relationship to aid HealthAmerica with managing its sleep disorder diagnostic expenses.

11 Oct 2011

FDA, other regulatory and international partners complete International Internet Week of Action

The U.S. Food and Drug Administration and other regulatory and international partners have completed the International Internet Week of Action (IIWA), a cooperative effort to curb online sales and distribution of counterfeit and illegal medical products.

30 Sep 2011

Sex therapy for prostate cancer after treatment may improve sex life: Study

Prostate cancer treatments can play havoc with men’s sex lives causing erectile dysfunction and other frustrating problems. For example, a recent study found about 60 percent of men with prostate cancer who had their prostate glands removed had not recovered their sexual function two years after their treatment. Many also lost some desire for sex and had a diminished ability to reach or enjoy orgasms. But new research shows that sex therapy can make a big difference.

27 Sep 2011

Couples counseling can benefit prostate cancer patients' sex lives

Both internet-based counseling programs and face-to-face therapy sessions for couples improve the sex lives of prostate cancer survivors and their spouses. That is the finding of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society.

26 Sep 2011

Prediction models may effectively identify erectile function after prostate cancer surgery

The development of prediction models that included variables such as pretreatment sexual function, patient characteristics and treatment factors appear to be effective at predicting erectile function 2 years after prostatectomy, external radiotherapy, or brachytherapy for prostate cancer, according to a study in the September 21 issue of JAMA.

21 Sep 2011

Multiple abstracts on QNEXA presented at 47th EASD

VIVUS, Inc. today announced that multiple abstracts were presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting in Lisbon, Portugal. The presentations highlighted the long-term beneficial effects of QNEXA treatment in metabolically-impaired patients with prediabetes, diabetes, and metabolic syndrome.

17 Sep 2011

UIC researchers to conduct study on televised drug commercials

Do pharmaceutical ads educate patients and improve health -- or merely spur drug sales? Researchers at the University of Illinois at Chicago's Institute for Health Research and Policy will conduct the first comprehensive study of televised drug commercials using Nielsen Media Research and health care utilization data.

15 Sep 2011

VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting

VIVUS, Inc. today presented positive results from the avanafil phase 3 study in diabetics. In the REVIVE-Diabetes study (TA-302), male diabetics receiving avanafil had significant improvement in erectile function.

14 Sep 2011